Association of Self-Expanding Valves with Increased Capture of Larger Debris by Cerebral Protection System in Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis.

Background: Mixed evidence exists regarding stroke rates when comparing self-expanding valves (SEVs) to balloon-expandable valves (BEVs) in transcatheter aortic valve replacement (TAVR). This study investigates the debris captured by the SENTINEL cerebral protection system (CPS) during TAVR.

Methods: Seventy-five consecutive patients who underwent TAVR with CPS from March to December 2023 were recruited.

Concurrent occurrence of adenocarcinoma and urothelial carcinoma of the prostate gland: A case report.

Background: Adenocarcinoma is the most common subtype of prostate cancer. Prostatic urothelial carcinoma (UC) typically originates from the prostatic urethra. The concurrent occurrence of adenocarcinoma and UC of the prostate gland is uncommon.

CD94 natural killer cells potentiate pulmonary ischaemia-reperfusion injury.

Background: Pulmonary ischaemia-reperfusion injury (IRI) is a major contributor to poor lung transplant outcomes. We recently demonstrated a central role of airway-centred natural killer (NK) cells in mediating IRI; however, there are no existing effective therapies for directly targeting NK cells in humans.

Methods: We hypothesised that a depleting anti-CD94 monoclonal antibody (mAb) would provide therapeutic benefit in mouse and human models of IRI based on high levels of (CD94) transcripts in bronchoalveolar lavage samples from lung transplant patients.

Comparable efficacy and safety for bicuspid aortic valve stenosis patients undergoing transcatheter aortic valve replacement with balloon-expandable or self-expanding valves using Wei's sizing method.

Background: The present study aimed to investigate whether proper sizing can improve the procedural and clinical outcomes of transcatheter aortic valve replacement (TAVR) with new-generation self-expanding valves (SEVs) and balloon-expandable valves (BEVs) for treating bicuspid aortic stenosis (BAS).

Methods: We retrospectively evaluated consecutive patients who underwent TAVR with Sapien 3 valves (Edwards Lifesciences, Irvine, CA) or Evolut R/PRO valves (Medtronic, Minneapolis, MN) for severe BAS from 2017 to 2022. The primary endpoints were device success rate and major adverse cardiac and cerebral events (MACCEs), including mortality, nonfatal myocardial infarction or disabling stroke, transcatheter heart valve failure, or clinically relevant valve thrombosis during follow-up.